The THOR project aims to combine human genetics and functional smooth muscle cells (SMC) studies to identify the expressed genes, pathways and functions that are linked to the development of atherosclerosis. By doing do, the THOR team hopes to find new and promising drug targets for the treatment of atherosclerosis. Novo Nordisk is industry partner in THOR.
In ODIN, all findings and results will be shared openly.
Researchers working on ODIN projects are encouraged to upload all of their findings to the ODIN community on Zenodo - see the link to the right.
If you have any questions, you are more than welcome to contact the ODIN secretariat.